Markets:

Overview

News

Currencies

International

Treasuries

Merus N.V. - Common Shares (NQ:MRUS)

90.00 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Merus N.V. - Common Shares

< Previous 1 2 3 4 Next >

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Via The Motley Fool

Topics Regulatory Compliance

What a $19 Million CyberArk Buy Signals for Long-Term Investors Amid a 43% Stock Surge ↗

December 23, 2025

The stock has already soared, the numbers keep accelerating, and one concentrated fund just made it a core holding anyway.

Via The Motley Fool

Topics Regulatory Compliance

What a $22 Million Bet on STAAR Surgical Signals After Third-Quarter Earnings and a 15% Market Lag ↗

December 23, 2025

The stock is roughly flat this past year, but the fundamentals quietly moved in the right direction, and that disconnect likely caught this fund’s attention.

Via The Motley Fool

Topics Regulatory Compliance

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal ↗

September 30, 2025

Via Stocktwits

Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race ↗

September 28, 2025

Via Stocktwits

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

Via The Motley Fool

Topics Regulatory Compliance

Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗

December 03, 2025

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Via The Motley Fool

Topics Regulatory Compliance

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

Unusual volume stocks are being observed in Thursday's session. ↗

October 02, 2025

In today's session, these stocks are experiencing unusual volume.

Via Chartmill

This Maplebear Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

September 30, 2025

Via Benzinga

Wall Street Lights Up as Cannabis Stocks Blaze Higher, Biotech Melts Down ↗

September 30, 2025

U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by...

Via Chartmill

Topics Cannabis

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Via MarketMinute

Let's take a look at the stocks that are in motion in today's session. ↗

September 29, 2025

Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings ↗

September 29, 2025

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday. The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 29, 2025

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44....

Via Benzinga

Top stock movements in today's session. ↗

September 29, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Tilray Brands, SNDL, Innoviz Technologies, Pony AI And Other Big Stocks Moving Higher On Monday ↗

September 29, 2025

U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Monday. Shares of Tilray Brands, Inc. (NASDAQ: TLRY) rose sharply during Monday's session.

Via Benzinga

Topics Artificial Intelligence Stocks

There are notable gap-ups and gap-downs in today's session. ↗

September 29, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough ↗

September 29, 2025

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V.

Via Benzinga

Expert Outlook: Merus Through The Eyes Of 4 Analysts ↗

September 29, 2025

In the preceding three months, 4 analysts have released ratings for Merus (NASDAQ: MRUS), presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent...

Via Benzinga

Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus ↗

September 29, 2025

The takeover candidate is working on a bispecific antibody, capable of simultaneously blocking two drivers of cancer.

Via Investor's Business Daily

Topics Government

Wondering what's happening in today's pre-market session? ↗

September 29, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 29, 2025

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.

Via Benzinga

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket ↗

September 29, 2025

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its...

Via Benzinga

MERUS NV (NASDAQ:MRUS) - A Technical Breakout Candidate Worth Watching ↗

July 14, 2025

MERUS NV (NASDAQ:MRUS) shows strong technicals with a 7/10 rating and a high-quality 9/10 setup, suggesting a potential breakout above $56.23. Support at $52.32-53.52 provides a clear risk level.

Via Chartmill

CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 04, 2025

Via Benzinga

e.l.f Beauty, Box And Joby Aviation Are Among Top 11 Mid-Cap Gainers Last Week (May 26-May 30): Are Others In Your Portfolio? ↗

June 01, 2025

11 mid-cap stocks soared last week, including LZ Technology, Centrus Energy, e.l.f Beauty, Merus, Oklo, NuScale Power, Informatica, BRP, Box, Joby Aviation, and C3.ai.

Via Benzinga

D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio? ↗

May 25, 2025

Top mid-cap stocks gained up to 53.47% in the last week, including QBTS, RGC, AAP, MRUS, OKLO, SBSW, and BGM. Are they in your portfolio?

Via Benzinga

Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On? ↗

May 23, 2025

Merus N.V. (NASDAQ: MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.